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Abstract
Compelling support for a central role for interferon-alpha in lupus
pathogenesis has led to a new focus on the role of innate immune
system activation in the generation of pathogenic mediators. These
insights have been extended in translational studies of patients
with well-characterized disease activity and clinical manifestations
in order to identify informative molecular biomarkers. Chemokines
are among the interferon-inducible genes, and new data support
an association between the expression of chemokines and both
lupus disease activity and organ damage. Longitudinal studies that
relate molecular biomarkers to disease activity will be needed to
validate these promising data and establish a sensitive measure of
change for interventional studies and patient care.
The translation of new concepts regarding the innate immune
response to the study of patients with systemic lupus
erythematosus (SLE) has led to advances in understanding
lupus pathogenesis. The identification of biomarkers that
reflect those pathogenic mechanisms holds promise of
extending those discoveries to improve patient care [1].
Current concepts incorporate a role for endogenous Toll-like
receptor ligands, including immune complexes containing
host-derived nucleic acids, in the initiation and amplification
of immune responses [2-4]. Those immune complexes can
induce type I interferon (IFN) and other inflammatory media-
tors that contribute to autoimmunity and inflammation. Among
the functional effects of IFN-α is the generation of proinflam-
matory mediators, including chemokines that direct the
trafficking of inflammatory cells. Through its regulation of
chemokines, IFN-α provides a link between innate immune
system activation by immune complexes and the charac-
teristic tissue damage seen in SLE patients.
In parallel with progress in defining immunopathogenic mecha-
nisms that underlie SLE, the development of immune system-
targeted therapeutics is increasing activity in interventional
clinical trials. Unfortunately, the drug development process in
SLE faces daunting challenges. The inherent heterogeneity of
lupus patients and the difficulty in clearly defining a meaningful
and quantifiable clinical outcome are limiting the success of
trials of promising and rationally designed biologics.
It is in the context of this new understanding of the central
role of the IFN pathway, along with the urgent need for
improved and biologically meaningful measures of disease
characteristics and activity, that research to define lupus
biomarkers is accelerating. In the previous issue of Arthritis
Research & Therapy, Fu and colleagues [1] presented cross-
sectional data that are based on a cohort of SLE patients,
rheumatoid arthritis (RA) patients, and healthy donors and
that support the potential utility of measuring chemokine
transcripts in peripheral blood as an indicator of disease
activity. Their study builds on a growing literature that has
used microarray, real-time polymerase chain reaction, or
functional assays of IFN-α activity to quantify activation of the
IFN pathway [5-7]. The measurement of serum chemokine
protein has been proposed as an additional approach to
define biologically and clinically meaningful changes in
disease activity [8,9].
As chemokine gene transcription is ‘downstream’ of IFN-α,
the authors measured chemokine transcripts and related
those data to various clinical parameters. A panel of seven
chemokine genes was selected based on evidence of their
induction by IFN-α. It should be noted, however, that in
contrast to the IFN-inducible genes that are highly specific for
response to type I IFN, including those used in the study of
Fu and colleagues to define an IFN score (such as IFIT1,
IFIT3, MX1, OAS1, and Ly6e), the chemokine gene products
studied (such as RANTES, MCP-1, MIG, IP-10, CXCL11, IL-8,
and  CCL19) can be induced by a wide variety of stimuli,
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including IFN-γ, tumor necrosis factor, growth factors, and
bacterial and viral products. The IFN score, then, is a fairly
specific measure of type I IFN activity (or induction by a virus),
while measurement of chemokine gene expression provides a
biomarker that integrates the composite effects of multiple
exogenous and endogenous stimuli, including type I IFN but
also a range of other influences. For that reason, a panel of
chemokine transcripts (or chemokine proteins) might be
predicted to provide a measure of a broader complement of
molecular influences that result in flares of disease activity or
augmented inflammation in a target organ.
The data presented by Fu and colleagues [1] indicate that a
composite score based on chemokine gene expression in
peripheral blood leukocytes is significantly associated with
lupus disease activity, as assessed by the SLEDAI-2K
(Systemic Lupus Erythematosus Disease Activity Index 2000)
or C3 levels. The chemokine score showed a slightly greater
degree of correlation with disease activity than did an IFN
score and was said to be more specific for SLE, as the IFN
score was also elevated in RA patients. Among the promising
data are those showing significantly higher chemokine scores
in patients with active lupus nephritis compared with those with
inactive lupus nephritis, although this effect was blunted in the
patients treated with at least 30 mg of prednisone daily.
Nonetheless, the data suggest that the chemokine score might
be a candidate for validation as a biomarker of those requiring
aggressive immunosuppressive therapy for lupus nephritis.
While the IFN and chemokine gene expression scores were
correlated with each other, the degree of correlation was
weak, consistent with the chemokine score reflecting diverse
stimuli, including but not restricted to IFN-α. In addition, the
presence of a chemokine score in some patients who did not
express an IFN score implicates molecular pathways other
than that induced by IFN in those patients. The data
presented are consistent with previous studies that focused
on serum chemokines and that also demonstrated an
association with increased disease activity [8,9].
Neither chemokine nor IFN-induced transcripts are likely to
be useful as a diagnostic biomarker specific for SLE. Although
relative specificity of increased chemokine transcript expres-
sion for SLE compared with RA was observed in the study of
Fu and colleagues, many conditions, including infections and
metabolic syndrome, also demonstrate increased expression
of chemokines. IFN-inducible gene expression is increasingly
recognized as a feature of a number of systemic autoimmune
diseases, including systemic sclerosis, polymyositis, dermato-
myositis, Sjögren syndrome, and RA. But measurement of
IFN-inducible gene expression should be valuable for
selection of patients and demonstration of effective blockade
of IFN in clinical trials targeting that pathway and might
predict future flares in some patients. In contrast, chemokine
expression may be a useful measure of more generalized
inflammation that suggests ongoing target organ damage.
Beyond their utility in defining relationships between immuno-
logic mediators and clinical parameters, these biomarker data
should stimulate further analysis of immunologic stimuli,
receptors, and signaling pathways distinct from those that
result in IFN pathway activation. For example, immune
complexes derived from lupus patients with arthritis induce
significantly higher levels of IL-8 than those from lupus
patients without arthritis, a function that does not depend on
the presence of DNA or RNA [10].
The demonstration of associations of chemokine and IFN
scores with disease activity and, in some studies, lupus
nephritis should stimulate multicenter longitudinal studies to
determine the relative value of these scores, along with
measurements of serum chemokine and IFN proteins or
functional activity, as measures of disease activity over time.
Validation of a biomarker useful for selection of patients for
clinical trials, prediction of disease flares, or measurement of
response to therapy could move lupus clinical research
toward its holy grail: approval of effective new therapies.
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